Duopharma Biotech Bhd's Total Assets for the quarter that ended in Mar. 2026 was RM1,446.5 Mil.
During the past 12 months, Duopharma Biotech Bhd's average Total Assets Growth Rate was 2.90% per year.
During the past 3 years, the average Total Assets Growth Rate was 2.90% per year.
During the past 5 years, the average Total Assets Growth Rate was 4.40% per year.
During the past 10 years, the average Total Assets Growth Rate was 9.40% per year.
During the past 13 years, Duopharma Biotech Bhd's highest 3-Year average Total Assets Growth Rate was 44.00%. The lowest was 2.60%. And the median was 11.80%.
Note:
The Net Income data used here is four times the quarterly (Mar. 2026) data.
In the article Joining The Dark Side: Pirates, Spies and Short Sellers, James Montier reported that In their US sample covering the period 1968-2003, Cooper et al find that firms with low asset growth outperformed firms with high asset growth by an astounding 20% p.a. equally weighted. Even when controlling for market, size and style, low asset growth firms outperformed high asset growth firms by 13% p.a. Therefore a company with fast asset growth may underperform.
Total Assets is linked to total revenue through Asset Turnover.
Duopharma Biotech Bhd's Asset Turnover for the quarter that ended in Mar. 2026 is
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Therefore, if a company grows its Total Assets faster than its Revenue, the Asset Turnover will decline. This might be a warning sign for the business.
Duopharma Biotech Bhd Total Assets Related Terms
Duopharma Biotech Bhd Total Assets Historical Data
* Premium members only.
The historical data trend for Duopharma Biotech Bhd's Total Assets can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
From the capital sources of the assets, some of the assets are funded through shareholder's paid in capital and retained earnings of the business. Others are funded through borrowed money.
Duopharma Biotech Bhd's Total Assets for the fiscal year that ended in Dec. 2025 is calculated as
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Duopharma Biotech Bhd (XKLS:7148) has a Total Assets of RM1,446.5 Mil as of Mar. 2026. The total amount of assets as recorded on a company's balance sheet. View historical data on Duopharma Biotech Bhd and its competitors.
Is Duopharma Biotech Bhd's Total Assets too high?
Duopharma Biotech Bhd's current Total Assets is RM1,446.5 Mil. Overall, Duopharma Biotech Bhd has a GF Score™ of 83/100 and is considered Modestly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Duopharma Biotech Bhd's Total Assets compare to ZTS and UTHR?
Duopharma Biotech Bhd's Total Assets of RM1,446.5 Mil can be compared against companies in the Drug Manufacturers industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Total Assets for a Drug Manufacturers company?
A good Total Assets depends on the Drug Manufacturers industry context. However, Total Assets should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Total Assets mean?
A high Total Assets can signal that a stock is expensive relative to its fundamentals. The total amount of assets as recorded on a company's balance sheet. View historical data on Duopharma Biotech Bhd and its competitors. Duopharma Biotech Bhd's current Total Assets is RM1,446.5 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Duopharma Biotech Bhd stock overvalued right now?
Based on GuruFocus' analysis, Duopharma Biotech Bhd (XKLS:7148) is currently considered Modestly Undervalued. The stock's GF Value™ is RM1.53, compared to a current price of RM1.24 — trading 19% below its estimated fair value. The current Total Assets is RM1,446.5 Mil. Duopharma Biotech Bhd's overall GF Score™ is 83/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Total Assets calculated?
Total Assets is calculated from a company's financial statements. For Duopharma Biotech Bhd (XKLS:7148), the current Total Assets is RM1,446.5 Mil as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Duopharma Biotech Bhd (XKLS:7148) Overvalued in 2026?
Based on GuruFocus' analysis, Duopharma Biotech Bhd stock appears to be undervalued.
The current stock price of RM1.24 is trading 19% below its estimated GF Value™ of RM1.53.
GuruFocus considers Duopharma Biotech Bhd to be Modestly Undervalued.
Key valuation signals for XKLS:7148:
Total Assets: RM1,446.5 Mil
GF Value™: RM1.53 vs. price of RM1.24 (19% below fair value)
No single metric tells the full story. See the XKLS:7148 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Duopharma Biotech Bhd is an investment holding company engaged in manufacturing pharmaceuticals. The company develops, manufactures, and markets generic and over-the-counter pharmaceutical products. The operating segment of the company is the manufacturing and distribution of pharmaceutical products. The principal activities of its subsidiary are to carry out business as a manufacturer, distributor, importer, and exporter of pharmaceutical products and medicines. Geographically, the company generates the majority of its revenue from Malaysia.
83GF Score
Get the complete analysis for XKLS:7148
Total Assets is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
XKLS:7148 has been successfully added to your 
